ALNY vs. HALO: Alnylam Pharmaceuticals vs. Halozyme Therapeutics Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and Halozyme Therapeutics (HALO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and Halozyme Therapeutics (HALO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ALNY | HALO |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | Halozyme Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 20.89 billion USD | 11.81 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2004 | March 16, 2004 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | HALO |
|---|---|---|
| Total Return (1Y) | -64.57% | 50.94% |
| Total Return (3Y, Annualized) | -1.58% | 41.08% |
| Total Return (5Y, Annualized) | -3.13% | 21.68% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | HALO |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 41.19% |
| Beta (5Y) | 0.45 | 0.96 |
| Max Drawdown (5Y) | -68.25% | -49.06% |
| Avg. Volume (3M) | 1.90M | 2.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | HALO |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 1.13 |
| Sortino Ratio (1Y) | -1.45 | 1.78 |
Profitability
ROE (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 138.07% and Halozyme Therapeutics (HALO) at 216.38% turn shareholders’ equity into profit at rates above their industry benchmark ranges for ROE. That is a strong capital-efficiency signal, though leverage and the equity base still matter.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 52.85% and Halozyme Therapeutics (HALO) at 26.93% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | HALO |
|---|---|---|
| ROE (TTM) | 138.07% | 216.38% |
| ROA (TTM) | 9.51% | 22.42% |
| Net Margin (TTM) | 52.85% | 26.93% |
| Operating Margin (TTM) | 23.72% | 59.84% |
| Gross Margin (TTM) | 77.28% | 77.74% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Halozyme Therapeutics (HALO) at 37.55% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.
Growth Metrics
| Metric | ALNY | HALO |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 37.55% |
| Revenue Growth (3Y CAGR) | 52.98% | 28.38% |
| EPS Growth (YoY) | -- | -25.36% |
| EPS Growth (3Y CAGR) | -- | 21.14% |
Financial Strength
Current Ratio (MRQ)
Both Alnylam Pharmaceuticals (ALNY) at 2.48 and Halozyme Therapeutics (HALO) at 3.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Alnylam Pharmaceuticals (ALNY) carries debt-to-equity ratio of 0.83 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
Financial Strength Metrics
| Metric | ALNY | HALO |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 3.88 |
| Debt / Equity (MRQ) | 0.83 | -- |
| Net Debt / EBITDA | -0.57 | 1.90 |
Dividends
Dividend Yield (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | HALO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Halozyme Therapeutics (HALO) at 25.91 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Halozyme Therapeutics (HALO) at 6.55 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 5.79, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
Valuation Metrics
| Metric | ALNY | HALO |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | 25.91 |
| P/S Ratio (TTM) | 4.17 | 6.55 |
| P/B Ratio (MRQ) | 5.79 | -213.67 |
| Free Cash Flow Yield (TTM) | 1.57% | 3.48% |